XOMA Royalty Corp.

NASDAQ:XOMA

Biotechnology

Healthcare
$40.17 +0.44%

+$0.19 today

Market cap
$503.77M
Beta
0.87
P/E (TTM)
15.8
EPS (TTM)
$2.65
52W Low $22.29High $42.81

Volume 4.22M

Average 0.21M

XOMA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

XOMA Royalty Corp.NASDAQ: XOMA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $11.86M rose 45.6% year over year, ahead of the -35.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.9% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.

Context

  • Selling, general & admin amounted to 69.2% of revenue in FY2025, down 51.8 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $145.75M (+303.8%) for the fiscal year ending Dec 2026, a step up from the +4.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.86M+13.9% QoQ
Last fiscal yearDec 2025
$36.09M+4.7% YoY
LTMMar 2026
$39.8M-35.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.6%+328.0%+282.5 pp
1 year+4.7%+303.8%+299.1 pp
3-year CAGR+15.9%+59.6%+43.7 pp
5-year CAGR+39.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
36.09M USD
Year-over-year change
+4.7%
4-year CAGR
+15.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How XOMA compares with its peers on the latest reported figures

  • XOMA's LTM Mar 2026 selling, general & admin of $39.8M is the 5th highest of the 10 companies compared; the peer median is $34.74M.
  • Its year-over-year change of -35.2% is the lowest of 10, against a peer median of +11.6%.
  • Selling, general & admin amounts to 109.9% of revenue for XOMA, versus a peer median of 1224.6%.
XOMA Competitors Peer median
Selling, General & Admin for XOMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$142.24M +17.3%+60.5%153.6%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$75.11M -30.1%+13.7%—
QSIQuantum-Si incorporatedLTM Mar 2026$42.51M -16.5%+1.9%2295.5%
SLDBSolid Biosciences Inc.LTM Mar 2026$40.91M +18.8%+10.3%—
XOMAXOMA Royalty Corp.LTM Mar 2026$39.8M -35.2%+15.9%109.9%
BNTCBenitec Biopharma Inc.LTM Mar 2026$34.74M +87.8%+52.2%—
AURAAura Biosciences, Inc.LTM Mar 2026$23.71M +3.3%+7.6%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$20.62M +11.6%+2.3%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$9.79M +21.7%+16.7%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$6.23M +9.7%-4.3%—
Peer median (excluding XOMA) $34.74M+11.6%+10.3%1224.6%

Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.16M6.03M4.76M28.49M52.15M
Cost of Revenue171K274K143K206K2.96M
Gross Profit37.99M5.75M4.62M28.28M49.18M
Gross Margin99.6%95.5%97.0%99.3%94.3%
Research & Development171K153K143K2.88M1.71M
Selling, General & Admin20.46M23.19M27.18M34.48M36.09M
Operating Expenses20.46M23.17M46.46M68.26M37.79M
Depreciation & Amortization167K274K900K216K2.97M
EBITDA16.52M(16.85M)(22.56M)(5.42M)47.82M
EBITDA Margin43.3%-279.5%-474.2%-19.0%91.7%
Operating Income17.53M(17.41M)(41.85M)(39.98M)11.38M
Operating Margin45.9%-288.9%-879.5%-140.3%21.8%
Interest Income0694K000
Interest Expense461K0569K13.84M13.03M
Other Income / Expenses(1.64M)295K1.02M20.5M20.43M
Income Before Tax15.89M(17.12M)(40.83M)(19.48M)31.82M
Pre-Tax Margin41.6%-284.0%-858.2%-68.4%61.0%
Income Tax Expense91K(15K)0(5.66M)103K
Net Income15.8M(17.1M)(40.83M)(13.82M)31.71M
Net Margin41.4%-283.8%-858.2%-48.5%60.8%
EPS (Basic)0.69(1.98)(4.04)(1.65)1.53
EPS (Diluted)0.65(1.98)(4.04)(1.65)1.46
Weighted Avg Shares11.29M11.41M11.47M11.7M17.98M
Weighted Avg Shares (Diluted)12.19M11.41M11.47M11.7M17.98M

XOMA Royalty Corp.

NASDAQ:XOMA

Intrinsic Alpha fair value

Locked

Current Price

$40.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.